Analyst Price Targets — INDV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 9:13 am | Glen Santangelo | Barclays | $43.00 | $36.50 | TheFly | Indivior price target lowered to $43 from $46 at Barclays |
| August 4, 2026 1:10 pm | Chase Knickerbocker | Craig-Hallum | $53.00 | $36.94 | TheFly | Indivior price target raised to $53 from $50 at Craig-Hallum |
| June 18, 2026 8:43 am | — | Barclays | $46.00 | $37.93 | TheFly | Indivior initiated with an Overweight at Barclays |
| January 20, 2026 2:08 pm | — | Northland Securities | $50.00 | $33.05 | TheFly | Indivior price target raised to $50 from $40 at Northland |
| January 12, 2026 11:04 am | — | H.C. Wainwright | $48.00 | $35.44 | TheFly | Indivior price target raised to $48 from $35 at H.C. Wainwright |
| December 3, 2025 11:32 am | — | Morgan Stanley | $36.00 | $34.00 | TheFly | Indivior price target raised to $36 from $28 at Morgan Stanley |
| October 31, 2025 1:25 pm | — | Craig-Hallum | $41.00 | $29.27 | TheFly | Indivior price target raised to $41 from $34 at Craig-Hallum |
| October 31, 2025 1:16 pm | — | Northland Securities | $40.00 | $29.67 | TheFly | Indivior price target raised to $40 from $30 at Northland |
| October 30, 2025 4:26 pm | Brandon Folkes | H.C. Wainwright | $35.00 | $29.14 | TheFly | Indivior price target raised to $35 from $28 at H.C. Wainwright |
| August 27, 2025 1:06 pm | Chase Knickerbocker | Craig-Hallum | $34.00 | $24.51 | TheFly | Indivior price target raised to $34 from $27 at Craig-Hallum |
Latest News for INDV
RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (such…
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 83,088 shares of the company's stock, valued at approximately $3,409,000. HighTower Advisors LLC owned about 0.07% of Indivior at the
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. U
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here to learn more about their rights and options or contact…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INDV.
U.S. House Trading
No House trades found for INDV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.